OTC: VNOV

Starting from July 30,
2021, the Company commenced its operation in the rendering of business consulting service to domestic and international customers. The
Company provides consulting services to its clients with regards to funding and other financial matters.

During the year ended April 30, 2026, we started new product line of
sale of healthy food products like olive juice, white sesame oil, aloe vera drink, etc.

Corporate History and Structure

We were incorporated
on January 25, 2017, under the laws of the State of Nevada, United States of America, formerly known as Soldino Group Corp. On November
15, 2018, the Company changed its name to Yijia Group Corp. On January 9, 2026, the Company changed its name to VitaNova Life Sciences
Corporation, and the ticker symbol of the Company’s common stock changed to “VNOV.”

On November 9, 2023,
the Company founded NutriPeak Trading Corporation, a wholly owned subsidiary incorporated in Nevada.

On March 6, 2026, the
Company founded VitaNova Global Foods Corporation (“VGFC”), a wholly owned subsidiary incorporated in Nevada. VGFC was established
with the purpose of marketing and supplying healthy food products.

Our organizational chart
is below:

1

November
2025 Change of Share Capital

On November 12, 2025,
the Company filed a Certificate of Amendment to the Articles of Incorporation to increase the number of authorized shares of Common Stock
and to authorize the issuance of blank check preferred stock. In particular, the total number of shares of capital stock that the Company
is authorized to issue was increased to 210,000,000, consisting of 200,000,000 shares of Common Stock, and 10,000,000 shares of initially
undesignated preferred stock, par value $0.001 per share (the “Preferred Stock”).

November
2025 Series A Preferred Stock

On November 21, 2025,
the Company filed a Certificate of Designation (the “Certificate of Designation”), pursuant to which the Company designated
3,000,000 shares of its authorized Preferred Stock as shares of Series A Preferred Stock. The Certificate of Designation sets forth the
powers, preferences, rights, qualifications, limitations and restrictions of the Series A Preferred Stock.

January 2026
Reverse stock split

On January 27, 2026, the Company’s 1-for-3 reverse stock split of its
common stock became effective, pursuant to which each holder of common stock received one share for every three shares held.

Our Brands and Product
Strategy

Our consumer-health operations
are managed through a dual-brand structure consisting of GeneCode® and AMZ®. This structure enables the
Company to address distinct consumer segments within the global dietary supplement industry while sharing research, manufacturing, and
marketing infrastructure. The approach is intended to promote scalability, consistent quality, and efficient allocation of resources.

The Company’s dual-brand
system combines a science-oriented platform with a high-volume functional-nutrition line. Both brands operate under unified oversight
from the Company’s product-development and regulatory-compliance teams.

Brand
Strategic Role

Market Focus

GeneCode®
GeneCode® is positioned as a wellness brand offering formulations developed through an internal review process that considers publicly available nutritional-science literature, ingredient-level research, and supplier technical data. This process is intended to support responsible ingredient selection and general-wellness product design. GeneCode® formulations are designed solely to support normal physiological functions such as routine energy metabolism, general vitality, and overall well-being.

GeneCode® targets consumers seeking
wellness-oriented formulations informed by commonly discussed nutritional-science topics and publicly available ingredient-level information,
which we reference internally for formulation context only and do not treat as evidence of the safety or effectiveness of our finished
products. These studies are referenced internally for formulation context only and do not evaluate or validate the Company’s finished
products. GeneCode® products are not clinically tested and are not intended to diagnose, treat, cure, or prevent any disease.

AMZ®
AMZ® serves as the Company’s functional-nutrition line, offering practical, accessible dietary-supplement formulations intended to support routine nutritional needs and daily-wellness maintenance. The brand emphasizes broad consumer reach, value accessibility, and lifestyle-oriented product design, while operating under the same manufacturing and regulatory compliance oversight as the GeneCode® line.

AMZ® is tailored to consumers seeking everyday nutritional support delivered through familiar, functional-nutrition categories such as metabolic balance, digestive wellness, and general vitality. AMZ® does not incorporate scientific-positioning language and is marketed strictly within the boundaries of U.S. dietary-supplement regulations.

2

We believe this structure allows the Company to
pursue differentiated marketing and pricing strategies while maintaining common manufacturing standards and supply-chain partners. We
believe each brand contributes distinct value: GeneCode® enhances the Company’s science-informed formulation processes
and focuses on ingredients with well-characterized nutritional roles. AMZ® expands reach within everyday functional-nutrition categories,
including metabolic support, digestive wellness and general vitality supplements, through accessible pricing and broad e-commerce exposure.
Together, we believe the dual-brand system enables diversified consumer coverage while maintaining a consistent compliance framework and
operational efficiencies.

Other Business Activities – Consulting

In addition to developing
and selling nutritional supplements under our GeneCode® and AMZ® brands, we also maintain a small consulting business that provides
general business-advisory and administrative support services to third parties. These services have historically included basic business-management
assistance, operational consulting, and related administrative support.

Other Business Activities – Sale of Healthy Food Products

During the year ended April 30, 2026, we started new product line of
sale of healthy food products like olive juice, white sesame oil, aloe vera drink, etc. VitaNova Global Foods Corporation, a wholly-owned
subsidiary incorporated in the State of Nevada, was formed to develop and expand the Company’s food trading business, including
the sourcing, distribution, import and export of healthy food products and related supply chain activities.

Although the food trading
business generated meaningful revenue shortly after its launch, management views this business primarily as source of revenue and cash
flow to support the Company’s broader operations.

Sales and Marketing

Our targeted, consumer-driven
marketing strategy has been key to building our brands and driving revenue growth. The Company utilizes a multi-channel sales and marketing
strategy to increase brand visibility, broaden consumer reach, and support revenue growth. Products are promoted through direct-to-consumer
channels, livestreaming platforms, retail partners, and wellness service networks, with a focus on science-based communication and targeted
outreach to consumers seeking science-informed wellness supplement solutions.

The Company leverages
social media, KOL and influencer collaborations, and community-driven content to strengthen brand trust and improve customer acquisition
efficiency. It also works with regional wellness providers and selected retail distributors to expand offline presence. The upcoming subscription
platform is expected to enhance customer retention, increase purchase frequency, and contribute to recurring revenue.

Management believes this
diversified approach enables the Company to effectively engage both online and offline consumers and supports scalable expansion in the
United States and internationally.

Research and Development

Our R&D activities
focus on reviewing publicly available scientific literature, supplier-provided technical information, and accepted nutritional-science
frameworks to inform ingredient selection, safety evaluations, and formulation design. All our products are marketed solely as dietary
supplements intended to support general health and wellness and are not intended to diagnose, treat, cure, or prevent any disease. We
do not conduct clinical trials on our finished products, and no scientific publication referenced in our R&D process evaluates or
validates the clinical performance, efficacy, or therapeutic effect of any formulation. Our R&D review is limited to evaluating regulatory
compliance, ingredient safety and general formulation considerations.

As part of our formulation
process, we review peer-reviewed, ingredient-level scientific literature addressing the general biological roles of nutritional compounds
commonly used in dietary supplements. This literature is used only to guide internal decisions regarding ingredient selection, dosage
ranges, and nutritional rationale. Our review includes research in fields such as nutritional biochemistry, cellular-energy metabolism,
botanical-extract characterization, and general wellness. These studies are not relied upon to claim any therapeutic or clinical effect
on our products.

3

Publicly available nutritional,
botanical, and scientific literature is widely referenced within the dietary-supplement industry to describe general ingredient categories,
historical usage, and broad scientific context. From time to time, we may review such publicly available materials as part of our internal
product-development process to better understand common ingredient classifications and industry practices. These materials are not relied
upon to evaluate, substantiate, or imply any effect of our finished products, nor do we represent that any external literature applies
to, supports, or assesses our formulations. Our products have not been clinically tested, and we do not claim that any scientific topic
discussed in external literature demonstrates or suggests the efficacy, biological effect, or health impact of our products.

Competition

The U.S. nutritional
supplements retail industry is a large and highly fragmented industry with few barriers to entry. We compete against other domestic and
international manufacturers, specialty retailers, mass merchants, multi-level marketing organizations, mail-order and direct-to-consumer
companies, and e-commerce companies. This market is highly sensitive to the introduction of new products, which may rapidly capture a
significant share of the market. Certain of our competitors may have significantly greater financial, technical and marketing resources
than we do, and may be able to adapt to changes in consumer preferences more quickly, devote greater resources to the marketing and sale
of their products, or generate greater brand recognition. In addition, our competitors may be more effective and efficient in introducing
new products.

Although there are
many competing products on the market across our product categories, we believe that the our brands are strengthened by formulations
developed using a science-informed approach and internal review of publicly available research without claiming clinical proof of
effectiveness. In response to intense market competition, our company focuses on continuous product innovation and development. We
strengthen our brand through advertising, participation in trade shows, and sponsoring public welfare projects. Flexible pricing
strategies, including promotions, coupons, and discounts, are employed to attract customers. Expanding into international markets
reduces reliance on a single market and opens up new opportunities. These initiatives enable us to navigate the competitive
landscape effectively.

Government Regulations

The U.S. Food
and Drug Administration

Dietary Supplements
and Foods

The Dietary Supplement
Health and Education Act of 1994 (“DSHEA”) amended the Federal Food, Drug, and Cosmetic Act (the “FD&C
Act”) to establish a framework governing the composition, safety, labeling, manufacturing, and marketing of dietary supplements.
Generally, under the FD&C Act, dietary ingredients (i.e., vitamins; minerals; herbs or other botanicals; amino acids; or dietary substances
for use by humans to supplement the diet by increasing total dietary intake; or any concentrate, metabolite, constituent, extract or combination
of any of the above) that were marketed in the United States prior to October 15, 1994 may be used in dietary supplements without
notifying the FDA. “New” dietary ingredients (i.e., dietary ingredients that were not marketed in the United States before
October 15, 1994) must be the subject of a new dietary ingredient notification submitted to the FDA unless the ingredient has been
“present in the food supply as an article used for food” without being “chemically altered.” A new dietary ingredient
notification must provide the FDA with evidence of a “history of use or other evidence of safety,” establishing that use of
the dietary ingredient “will reasonably be expected to be safe,” and must be submitted to the FDA at least 75 days before
the initial marketing of the new dietary ingredient. The FDA may determine that a new dietary ingredient notification does not provide
an adequate basis to conclude that a dietary ingredient is reasonably expected to be safe. Such a determination could prevent the marketing
of such dietary ingredients.

4

In 2011 and 2016, the
FDA issued draft guidance setting forth recommendations for complying with the new dietary ingredient notification requirement. In March
2024, the FDA issued final guidance regarding New Dietary Ingredient Notification (“NDIN”) procedures and timeframes, finalizing
the corresponding portions of its 2016 revised draft guidance and certain related questions. Other portions of the 2016 revised draft
guidance remain in draft form. Although FDA guidance is non-binding and does not establish legally enforceable responsibilities, and companies
are free to use an alternative approach if the approach satisfies the requirements of applicable laws and regulations, FDA guidance is
a strong indication of the FDA’s view on the topic discussed in the guidance, including its position on enforcement. We do not currently
anticipate that the final guidance or the remaining portions of the draft guidance will have a material effect on our operations. As a
part of our product development process, ingredients in products are vetted for compliance with the FDA’s regulations for dietary
supplements. Any ingredient suspected to fall under the NDIN classification is further vetted to determine whether an NDIN is required,
whether an applicable exemption is available and, if an NDIN is required, whether an appropriate notification covering the proposed conditions
of use has been submitted to the FDA. Ingredients are also separately evaluated for compliance with applicable food-additive requirements,
including Generally Recognized as Safe (GRAS) requirements, where applicable.

The FDA or other agencies
could take actions against products or product ingredients that, in their determination, present an unreasonable health risk to consumers
that would make it illegal for us to sell such products. In addition, the FDA could issue consumer warnings with respect to the products
or ingredients in such products that we sell. Such actions or warnings could be based on information received through the FD&C Act-mandated
reporting of serious adverse events.

The Public Health Security
and Bioterrorism Preparedness and Response Act of 2002 (the “Bioterrorism Act”), enacted in 2002, is a U.S. federal law
aimed at bolstering the nation’s ability to prevent, prepare for, and respond to bioterrorism and other public health emergencies.
Key provisions include mandatory registration of food facilities with the FDA, prior notification of imported food shipments, recordkeeping
requirements for food facilities, and the FDA’s authority to administratively detain food products posing serious health risks.
This legislation enhanced food safety by facilitating better monitoring of food facilities and imports, improving traceability and recall
efforts, and strengthening the FDA’s ability to respond swiftly to potential threats to public health.

In June 2007, pursuant
to the authority granted by the FD&C Act as amended by DSHEA, the FDA published detailed current Good Manufacturing Practice (“cGMP”)
regulations that govern the manufacturing, packaging, labeling, and holding operations of dietary supplement manufacturers. The cGMP regulations,
among other things, imposed significant recordkeeping requirements on manufacturers. The cGMP requirements are in effect for all dietary
supplement manufacturers, and the FDA conducts inspections of dietary supplement manufacturers pursuant to these requirements. The failure
of a manufacturing facility to comply with the cGMP regulations renders products manufactured in such facility “adulterated,”
and subjects such products and the manufacturer to a variety of potential FDA enforcement actions. In addition, the Food Safety Modernization
Act (“FSMA”), which was enacted in January 2011, aimed to modernize and strengthen the food safety system by shifting
the focus from responding to foodborne illness outbreaks to preventing them. The act granted the FDA new regulatory authority over the
way foods are grown, harvested, and processed. It also required food facilities to implement preventive controls to identify and address
potential hazards in their operations. FSMA represents a fundamental shift in food safety regulation, emphasizing prevention, risk-based
approaches, and enhanced collaboration throughout the food supply chain, which has increased the costs of dietary ingredients and has
subjected the suppliers of such ingredients to more rigorous inspections and enforcement. FSMA also requires importers of food, including
dietary supplements and dietary ingredients, to conduct verification activities under the Foreign Supplier Verification Program (“FSVP”)
to ensure that the food or ingredients they import meet applicable domestic requirements. The FDA applies modified FSVP requirements to
importers of dietary supplements and dietary supplement components: importers subject to dietary supplement cGMPs are generally excepted
from the full FSVP requirements other than the obligations to use a qualified individual and to identify the importer at entry, while
importers of dietary supplements not subject to those cGMPs must follow tailored FSVP requirements.

In addition, under FSMA
the FDA has adopted a Food Traceability Rule, which requires persons who manufacture, process, pack, or hold foods on the FDA’s
Food Traceability List to establish and maintain a traceability plan and to keep records of specified key data elements associated with
defined critical tracking events (such as initial packing, shipping, receiving, and transformation). The rule became effective January
20, 2023. The original compliance date for all persons subject to the recordkeeping requirements of the Food Traceability Rule was Tuesday,
January 20, 2026. The FDA proposed to extend the compliance date for the rule by 30 months to July 20, 2028.

5

We take several actions
to ensure that manufacturers we engage comply with the Bioterrorism Act, have implemented FSMA procedures (as applicable), and are operating
under cGMPs. As is common in our industry, we rely on our third-party suppliers and manufacturers to have policies and procedures that
ensure that the products they manufacture and sell to us comply with all applicable regulatory and legislative requirements. Internally,
we have a set of supplier onboarding procedures that ensure that the third-party facilities are registered with the FDA and are operating
a quality system up to cGMP standards for the respective product category. We make an intentional effort to engage manufacturers that
have additional quality certifications and third-party audits, such as food safety certifications under the Global Food Safety Initiative
(GFSI) or dietary supplement cGMP certifications audited by the National Sanitation Foundation (NSF), whenever possible. During this onboarding
process, the supplier’s history is also researched for any recent recalls, warning letters, or import alerts related to their facility
or products manufactured by the supplier. Additionally, each third-party manufacturer is required to enter into a quality agreement with
us. This document specifically outlines responsibilities and cGMP/documentation expectations for each party. In general, we also seek
representations and warranties, indemnification and/or insurance from our vendors. However, even with adequate insurance and indemnification,
any claims of non-compliance could significantly damage our reputation and consumer confidence in our products. In addition, the failure
of such products to comply with applicable regulatory and legislative requirements could prevent us from marketing the products or require
us to recall or remove such products from the market, which in certain cases could materially and adversely affect our business, financial
condition and results of operations. A removal or recall could also result in negative publicity and damage to our reputation which could
reduce future demand for our products. In such case, we may attempt to offset any losses related to recalls and removals with reformulated
or alternative products; however, there can be no assurance that we would be able to offset all or any portion of losses related to any
future removal or recall.

The FD&C Act permits
structure/function claims to be included in labels and labeling for dietary supplements without FDA pre-market approval. However, companies
must have substantiation that the claims are “truthful and not misleading,” and must submit a notification with the text of
the claims to the FDA no later than 30 days after marketing the dietary supplement with the claims. Permissible structure/function
claims may describe how a particular nutrient or dietary ingredient affects the structure, function, or general well-being of the body,
or characterize the documented mechanism of action by which a nutrient or dietary ingredient acts to maintain such structure or function.
Dietary supplement labeling bearing a structure/function claim must also include the prescribed disclaimer stating that the FDA has not
evaluated the claim and that the product is not intended to diagnose, treat, cure or prevent any disease. The label or labeling of a product
marketed as a dietary supplement may not expressly or implicitly represent that a dietary supplement will diagnose, cure, mitigate, treat,
or prevent a disease (i.e., a disease claim). If the FDA determines that a particular structure/function claim is an unacceptable disease
claim that causes the product to be regulated as a drug, a conventional food claim, or an unauthorized version of a “health claim,”
or, if the FDA determines that a particular claim is not adequately supported by existing scientific data or is false or misleading in
any particular way, we would be prevented from using the claim and would have to update our product labels and labeling accordingly. We
have an in-house regulatory team that reviews scientific literature and develops substantiation as part of the product development process
to ensure the crafting of compliant structure/function claims and product positioning.

In addition, DSHEA provides
that so-called “third-party literature,” e.g., “a publication, including an article, a chapter in a book, or an official
abstract of a peer-reviewed scientific publication that appears in an article and was prepared by the author or the editors of the publication”
supplements, when reprinted in its entirety, may be used “in connection with the sale of a dietary supplement to consumers”
without the literature being subject to regulation as labeling. Such literature: (1) must not be false or misleading; (2) may
not “promote” a particular manufacturer or brand of dietary supplement; (3) must present a balanced view or is displayed
or presented with other such items on the same subject matter so as to present a balanced view of the available scientific information;
(4) if displayed in an establishment, must be physically separate from the dietary supplements; and (5) should not have appended
to it any information by sticker or any other method. If literature fails to satisfy each of these requirements, we may be prevented from
disseminating such literature with our products, and any continued dissemination could subject our product to regulatory action as an
illegal drug.

The FDA has broad authority
to enforce the provisions of federal law applicable to dietary supplements, including powers to issue a public warning or notice of violation
letter to a company, publicize information about illegal products, detain products intended for import, require the reporting of serious
adverse events, require a recall of illegal or unsafe products from the market, and request the Department of Justice to initiate a seizure
action, an injunction action or a criminal prosecution in United States courts.

6

Federal Trade
Commission

The Federal Trade Commission
(the “FTC”) exercises jurisdiction over the advertising of all products, including foods, dietary supplements and cosmetics,
and requires that all advertising to consumers be truthful and not misleading. The FTC actively monitors the dietary supplement space
and has instituted numerous enforcement actions against dietary supplement companies for failure to have adequate substantiation for claims
made in advertising or for the use of false or misleading advertising claims or practices. These enforcement actions have resulted in
consent decrees and significant monetary judgments against the companies and/or individuals involved. Regulators require a company to
convey product claims clearly and accurately and further require marketers to maintain adequate substantiation for their claims. More
specifically, the FTC requires such substantiation to be based upon competent and reliable scientific evidence and requires a company
to have a reasonable basis for the expressed and implied product claim before it disseminates an advertisement. A reasonable basis is
determined based on the claims made, how the claims are presented in the context of the entire advertisement, and how the claims are qualified.
The FTC’s standard for evaluating substantiation is designed to ensure that consumers are protected from false and/or misleading
claims by requiring scientific substantiation of product claims at the time such claims are first made. The failure to have this substantiation
violates the Federal Trade Commission Act.

Foreign

Our products sold in
foreign countries are also subject to regulation under various national, local, and international laws that include provisions governing,
among other things, the formulation, manufacturing, packaging, labeling, testing, advertising, and distribution of these products within
their respective categories. Some foreign entities categorize these products/formulations as “Medicines” or subsets of a medicinal
category instead of as “food supplements” or “dietary supplements”, based on the regionally-specific regulations
and the nature of the product. Government regulations in foreign countries may prevent or delay the introduction or require the reformulation
of certain of our products.

Human Capital Resources

We recognize that attracting,
motivating and retaining passionate talent at all levels is vital to continuing our success. By improving employee retention and engagement,
we also improve our ability to support our customers and protect the long-term interests of our stakeholders and stockholders. We invest
in our employees through continuously improving benefits and various health and wellness initiatives, and offer competitive compensation
packages, working to continuously improve fairness in internal compensation practices.

As of the date of this
Annual Report, we had a total of 7 full-time employees. We intend to grow our employee
base in response to the demands and requirements of the business. We believe that the employer-employee relationships in our Company
are positive. We have no labor union contracts.

Insurance

As of the date of this
Annual Report, we do not maintain product liability insurance, clinical trial insurance, key person insurance, business interruption
insurance or other material commercial insurance coverage. We may seek to obtain one or more forms of insurance coverage in the future
as our operations grow and financial resources permit; however, there can be no assurance that we will be able to obtain such coverage
on commercially reasonable terms or at all.

Additional Information

We are a reporting issuer,
subject to the Exchange Act. Our Quarterly Reports, Annual Reports, and other filings can be obtained from the SEC’s Public Reference
Room at 100 F Street, NE., Washington, DC 20549. You may also obtain information on the operation of the Public Reference Room by calling
the SEC at 1-800-SEC-0330. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information
regarding issuers that file electronically with the SEC at www.sec.gov.

7